Nonprofit Acquires Discontinued ADC Luveltamab Tazevibulin to Preserve Compassionate Use Access for Children with Ultra-Rare Fatal Leukemia
核心洞察
Blood Cancer United (搜索) acquired the remaining supply of luveltamab tazevibulin (Luvelta), an antibody-drug conjugate targeting FOLR1 (搜索), after Sutro Biopharma discontinued development in March 2025.
The drug has shown meaningful benefit in CBFA2T3-GLIS2-rearranged AML (搜索), an ultra-rare pediatric leukemia with only 15–30% survival and approximately 17 new U.S. cases annually.
The nonprofit will distribute the drug at no cost through the FDA's compassionate use pathway, with current supply expected to last a few years and expiry through 2028.
In an unprecedented move to protect access to a promising therapy for children with an ultra-rare and frequently fatal leukemia, Blood Cancer United (搜索) announced on June 11, 2026 that it has acquired the remaining supply of luveltamab tazevibulin (Luvelta), an antibody-drug conjugate (ADC) targeting the Folate Receptor-1 (FOLR1 (搜索)). The drug, originally developed by Sutro Biopharma for adult lung and ovarian tumors, had its compassionate use program discontinued after the company halted development in March 2025 to prioritize other pipeline assets.
The acquisition marks what experts describe as a rare and potentially replicable model: a nonprofit stepping in to preserve access to a de-risked investigational therapy that would otherwise vanish due to commercial calculations, not clinical futility.
A Disease with Devastating Odds
Luveltamab tazevibulin has shown early promise for CBFA2T3-GLIS2-rearranged acute myeloid leukemia (AML), a molecularly defined subtype diagnosed in an estimated 17 children in the United States each year. This form of AML is resistant to conventional chemotherapy and carries a survival rate of only 15% to 30%.
"Because this disease is so rare, we don't have a lot of data but so far the investigational therapy has shown meaningful benefit, in some cases enabling deep remissions and allowing kids to proceed to bone marrow transplant, currently the only potentially curative option," said Gwen Nichols, M.D., chief medical officer of Blood Cancer United (搜索).
The organization's involvement with this disease subtype runs deep. Blood Cancer United (搜索) has invested more than $2 billion in research since its founding in 1949. This includes support for foundational work by James Downing, M.D., of St. Jude Children's Hospital that contributed to the identification of the CBFA2T3-GLIS2 rearrangement as a driver of this rare childhood AML, as well as multiple grants to Soheil Meshinchi, M.D., Ph.D., of Fred Hutchinson Cancer Center that led to the identification of FOLR1 (搜索) as a therapeutic target.
A Child's Story That Galvanized Action
The human stakes behind the acquisition are embodied by Aspen Peck, diagnosed with CBFA2T3-GLIS2-rearranged AML (搜索) around her first birthday. After relapsing following intensive chemotherapy and a bone marrow transplant, Aspen received luveltamab tazevibulin through compassionate use and has remained in remission since early 2022.
"When Aspen was diagnosed, we were told it would be a miracle if she made it to kindergarten — and she'll be finishing kindergarten next week," said Troy Peck, Aspen's father. "This drug gave our daughter another chance — and every family facing this diagnosis deserves that chance."
Troy Peck told STAT News that Aspen would not be alive without access to Luvelta, and her case has been used as a guide for treatment of other patients with similar disease presentations.
A Structural Gap in Pediatric Drug Development
The Luvelta situation illustrates a well-documented structural problem in rare disease drug development. Even with the best intent, drugmakers face economic realities when deciding whether to continue developing a medication unlikely to generate substantial revenue. Federal programs including the Orphan Drug Act provide financial aid for research and development, yet not all drugs are picked up and manufactured even with this designation.
The challenge is compounded for pediatric medications. Many drugs originate with adult indications and are used off-label in children. When adult development programs fail or are deprioritized, pediatric applications become collateral damage.
"It is unfortunately one of those stories that we hear too often, of drugs kind of being left behind," Crystal Mackall, M.D., a pediatric hematology and oncology specialist at Stanford University, told STAT. "The people who are losing are those individuals with rare diseases, and unfortunately children's cancer is the poster child for this."
The Transaction and Path Forward
As part of the transaction, Blood Cancer United (搜索) also acquired the investigational new drug designation and will manage the compassionate use program, distributing the medication to patients at no cost while supplies last. The organization's role is limited to preserving access to the existing supply and it will not commercialize the drug.
E. Anders Kolb, M.D., president and chief executive officer of Blood Cancer United (搜索), noted that with approximately 20 new patients who may use Luvelta annually, the organization anticipates having enough supply for a few years. The current supply has an expiry of 2028, and the organization plans to pursue stability testing for potential shelf-life extension.
"Families face a maze of operational hurdles, small trial populations and commercial calculations that can make a promising drug vanish," Kolb said. "We acquired the remaining supply of luveltamab tazevibulin to keep treatment available now, while we push for clearer regulatory paths, shared trial infrastructure and incentives so these therapies can be studied and sustained for the children who need them."
The effort is funded through Dare to Dream, a Blood Cancer United (搜索) project dedicated to transforming pediatric cancer treatment and care, including a gift from The Andrew McDonough B+ Foundation.
"This is just a terrific model for pediatric cancer drug development because the drug has been de-risked and so much has been invested in the drug in terms of research and development," said Nancy Goodman, patient advocate and founder of Kids v Cancer. "I hope this is a model we can replicate."
Kolb underscored the urgency driving the intervention: "I don't think we can overstate the fact that there are children alive today because of this drug. If we can get this drug to everybody who needs it, it's a thousand birthdays that may not have happened otherwise."